Related Experiment Video

Updated: Jun 15, 2025

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
00:06

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

8.8K

HBV reactivation and its management in HBV-related HCC patients undergoing HAIC-TKI-ICI therapy: A multicenter study

Jiayun Liu1,2,3, Bo Sun1,2,3, Jiahua Zou4

  • 1Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.

Iscience
|June 13, 2025
PubMed

This study aimed to assess hepatitis B virus (HBV) reactivation, its impact on prognosis, and its management in patients with HBV-related hepatocellular carcinoma (HCC), who received hepatic arterial infusion chemotherapy (HAIC) plus tyrosine kinase inhibitors (TKIs), immune checkpoint inhibitors (ICIs), and entecavir (HAIC+TKIs+ICIs+entecavir) treatments. Three hundred and seven patients in five centers with advanced HBV-related HCC, who received the quadruple treatment, were included. The HBV reactivation was observed in 44 (14.3%) patients. HBV-DNA level ≥1 × 104 IU/mL, positive HBeAg, and white blood cell count <4 × 109/L were the independent risk factors of HBV reactivation. The median progression-free survival and median overall survival of patients in the HBV non-reactivation group were significantly longer than those of patients in the HBV reactivation group (p < 0.001, p < 0.001). The additional treatment with tenofovir alafenamide fumarate can effectively manage the HBV reactivation and improve the survival of these HBV reactivated HCC patients.

Keywords:
CancerHealth sciencesVirology

More Related Videos

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice07:25

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

6.8K
Use of Single Chain MHC Technology to Investigate Co-agonism in Human CD8+ T Cell Activation12:09

Use of Single Chain MHC Technology to Investigate Co-agonism in Human CD8+ T Cell Activation

Published on: February 28, 2019

9.7K

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
493
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.6K
Retrovirus Life Cycles01:10

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the...
45.8K